Group items tagged

To foster innovative collaborative approaches to research projects that propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke. This award is also intended to foster collaboration between established and early- or mid-career investigators. Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before. Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems. Proposals are encouraged from all basic science disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems. AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, engineering, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, health attorneys, engineers, etc.).

The BDSRA is pleased to announce that funds are available to conduct research directly relevant to all forms of Neuronal Ceroid Lipofuscinosis (NCL, Batten disease), rare, fatal, lysosomal neurodegenerative disorders that strike infants, children and adults. Research is needed across a broad spectrum addressing the underlying mechanisms of neural dysfunction and degeneration in each form of NCL from dysfunctional soluble lysosomal enzymes (PPT1, TPP1, CTSD), transmembrane proteins (CLN3, CLN6, MFSD8, CLN8) and other proteins implicated in lysosome function, membrane trafficking, or neurotransmitter release (CLN5, CSPα). Proposals will be considered for all forms of NCL, with emphasis on CLN1, CLN2, and CLN3. 

The Presidential Awards for Excellence in Science, Mathematics, and Engineering Mentoring (PAESMEM) is a Presidential award established by the White House in 1995. The purpose of the award is to recognize U.S. citizens or permanent residents and U.S. organizations that have demonstrated excellence in mentoring individuals from groups that are underrepresented in science, technology, engineering, and mathematics (STEM) education and workforce. Groups that are underrepresented in STEM include women, people with disabilities, underrepresented racial and ethnic minorities, as well as individuals from low socio-economic backgrounds and some geographic regions such as urban and rural areas. The PAESMEM program is administered by the National Science Foundation (NSF) on behalf of the White House Office of Science and Technology Policy (OSTP). Nominations, including self-nominations, are invited for Individual and Organizational PAESMEM awards. Individuals and organizations in all public and private sectors are eligible including industry, academia, primary and secondary education, military and government, non-profit organizations, and foundations. Nominations are encouraged from all geographical regions in the U.S., its territories or possessions, particularly jurisdictions designated by Congress under NSF's Experimental Program to Stimulate Competitive Research (EPSCoR).

The Angelman Syndrome Foundation announces the availability of up to $1,000,000 (USD) to be awarded in support of research on Angelman syndrome. Angelman syndrome is a neurodevelopmental disorder caused by deficiency of the ubiquitin protein ligase UBE3A in the brain. Applications in the preclinical, translational and clinical research areas that investigate all aspects of Angelman syndrome will be considered. Highest priority will be given to pilot projects to test new ideas about pathogenesis and therapeutics of Angelman syndrome. Researchers from all countries are encouraged to apply.

This Funding Opportunity Announcement (FOA) intends to support a Brain Cell Data Center (BCDC) that will work with other BICCN Centers and interested researchers to establish a web-accessible information system to capture, store, analyze, curate, and display all data and metadata on brain cell types, and their connectivity. The BCDC is expected to: (1) lead the effort to establish spatial and semantic standards for managing heterogeneous brain cell census data types and information; (2) lead the effort to collect and register multimodal brain cell census data to common brain coordinate systems; (3) generate searchable 2D and 3D digital brain atlases for cell census data; and (4) generate a unified and comprehensive brain cell knowledge base that integrates all existing brain cell census data and information across diverse repositories.  A central goal of this and the three companion FOAs is to build a brain cell census resource that can be widely used throughout the research community.

Candidates must hold a Ph.D. (or equivalent) in chemistry, computational or evolutionary molecular biology, computer science, economics, mathematics, neuroscience, ocean sciences (including marine biology), physics, or a related field; Candidates must hold a tenure track (or equivalent) position at a college, university or other degree-granting institution in the United States or Canada;  Candidates must normally be no more than six years from completion of their most recent Ph.D. (or equivalent) as of the year of their nomination.  (That is, most recent Ph.D. must have been awarded on or after September 2007.)** While Fellows are expected to be at an early stage of their research careers, there should be strong evidence of independent research accomplishments. Candidates in all fields are normally below the rank of associate professor and do not hold tenure, but these are not strict requirements. The Alfred P. Sloan Foundation welcomes nominations of all candidates who meet the traditional high standards of this program, and strongly encourages the participation of women and members of underrepresented minority groups.

In September, Miami received notice from the government that our new F&A rates are: 44.5% for On Campus Organized Research 44.0% On Campus Sponsored Instruction 39.0% On Campus Other Sponsored Activities 26.0% Off Campus All Programs These rates are effective beginning September 1, 2014. Awards received beginning in September and all proposal submissions going forward will be required to use the new rates.

Sigma Xi, a society of research scientists and engineers that rewards excellence in research and cooperation among scientists in all fields, has been providing undergraduate and graduate students with valuable educational experiences and financial support for more than eighty years. By encouraging close working relationships between students and faculty, the society promotes scientific achievement through hands-on learning. Through the Sigma Xi Grants-in-Aid of Research program, the society awards grants of up to $1,000 to students from all areas of the sciences and engineering. Designated funds from the National Academy of Sciences allow for grants of up to $5,000 for astronomy research and $2,500 for vision-related research. Funding can support travel expenses or nonstandard laboratory equipment necessary to complete a specific research project. While membership in Sigma Xi is not a requirement for applying for funding, approximately 75 percent of Grants-in-Aid of Research funds are restricted for use by dues-paying student members or students whose project advisor is a dues-paying member. Students from any country are eligible to receive funding. Complete program guidelines and application instructions are available on the Sigma Xi Web site.

This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process.  It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.

As part of a network, Centers are expected to participate in collaborative efforts on a national scale. Applicants must agree to collect a standard clinical data set (the Uniform Data Set, or UDS) that is common to all Centers and to transmit that data to the National Alzheimer's Coordinating Center (NACC). Applicants should contact NACC to learn more about NACC procedures, the structure of the UDS, and the regular updates to the datasets required from all Centers at  http://www.alz.washington.edu/.  To support the unique research needs of the NACC, most Centers collect additional data to supplement those required by the UDS. These should also be made readily available to qualified investigators. Similarly, Centers should demonstrate a readiness to provide biological samples and data, with proper consent from well-characterized populations, to enable participation in large-scale, collaborative, national, or international research projects. Sample sharing may be done either locally or centrally through the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD). Centers are a local, regional, national, and international resource.

The PRARP Quality of Life Research Award (QUAL) mechanism was first offered in FY13. Since then, 38 QUAL applications have been received, and 16 have been recommended for funding. The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures. The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses. The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years.

Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures.The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses.The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.The research impact is expected to benefit the military, Veteran, and civilian communities. To this end, the PRARP has identified QUAL Overarching Challenges and Focus Areas by which the intent of this mechanism can be facilitated. These should be carefully considered as part of the application process.FY17 PRARP QUAL Overarching Challenges: T

Founded in 1972, the Tourette Association of America (formerly known as the Tourette Syndrome Association) has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders. To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies on all aspects of Tourette syndrome. To be eligible, investigators are required to have an advanced degree such as a Ph.D., M.D. or equivalent or be allied professionals with advanced degrees such as R.N.s, Drs. of O.T., social workers, and related fields. Investigators from nonprofit and for-profit organizations can apply.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

Annual Biomedical Research Conference for Minority Students Judges' Travel Subsidy First-time ABRCMS judges (postdoctoral scientists and faculty members) available to judge all poster and oral sessions scheduled throughout the conference are eligible to apply for the Judges' Travel Subsidy. The subsidy provides up to $1,500 to cover registration, housing and travel.

Within the framework of the For Women in Science partnership between the L'Oréal Foundation and UNESCO, we are launching the 2014 call for nominations for outstanding women scientist form all over the world. Five 100.000$ prizes will be awarded in march 2014 in Paris to five women scientists, one per region, for the contributions of their research, the strength of their commitments and their impact on society. An international Jury of eminent scientists presided in 2013 by the Nobel Prize winner, Ahmed Zewali, makes the final selection.

The Ethics Education in Science and Engineering (EESE) program funds research and educational projects that improve ethics education in all fields of science and engineering that NSF supports, with priority consideration given to interdisciplinary, inter-institutional, and international contexts.  Although the primary focus is on improving ethics education for graduate students in NSF-funded fields, the proposed programs may benefit advanced undergraduates as well.